You are here: Home » Markets » News
Business Standard

Pharma shares underperform in a firm market; Glenmark, Ipca Labs fall 6%

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex

Buzzing stocks | Markets | pharmaceutical firms

SI Reporter  |  Mumbai 

Pharma stocks, Pharma firms

Shares of pharmaceutical companies fell up to 6 per cent on Monday due to profit-booking even as the benchmark indices hit their respective record high levels.

Among individual stocks, and slipped 6 per cent, while Cipla, Laurus Labs, Neuland Laboratories, Caplin Point Laboratories, Strides Pharma Science and Novartis India were down in the range of 2 per cent to 4 per cent on the BSE.

At 12:47 pm, the S&P BSE Healthcare index, the sole loser among sectoral indices, was down 0.39 per cent, as compared to 1.1 per cent rise in the S&P BSE Sensex. The Sensex and Nifty50 indices hit their record highs level of 42,566.34 and 12,451.80 points, respectively, today in early morning trade.

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex. Prior to that, healthcare index had rallied 53 per cent during the calendar year 2020, against 2.6 per cent decline in the benchmark index.

fell 6 per cent to Rs 474 on the BSE. In the September 2020 quarter (Q2FY21) the company’s adjusted profit after tax down 9.7 per cent year-on-year (YoY) to Rs 231 crore. Revenues grew 4.9 per cent YoY to Rs 2,953 crore with 17.2 per cent YoY growth in domestic sales to Rs 1,051 crore due to additional contribution from Fabiflu (favipiravir) being partly offset by 11.3 per cent decline in US to Rs 752 crore. Ebitda (earnings before interest, taxes, depreciation, and amortisation) margins improved 272 bps YoY to 18.7 per cent mainly due to lower other expenditure, ICICI Securities said in a note.

Operationally, barring the US, other geographies are, more or less, looking stable led by domestic formulations. The brokerage firm believes reduction of debt, improvement in free cash flow and margins are key events to watch.

Ipca Lab’s Q2 results were below our estimates on all fronts due to lower than expected sales in the domestic formulations. Notwithstanding quarterly gyrations in domestic formulations, the company continues to thrive on exports front, both in formulations and APIs. Going ahead, with firm growth tempo in domestic formulations, good prospects both for API exports, formulation exports, we expect further improvement in financial parameters, ICICI Securities said. The stock slipped 6 per cent to Rs 2,196 on the BSE in intra-day trade today.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 09 2020. 13:32 IST